Literature DB >> 26005163

Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.

Tomas Jelinek1, Jakob P Cramer2, Sebastian Dieckmann3, Christoph Hatz4, Maria Paulke-Korinek5, Martin Alberer6, Emil C Reisinger7, Marco Costantini8, Dieter Gniel9, Dietrich Bosse9, Maria Lattanzi10.   

Abstract

BACKGROUND: For individuals traveling at short notice to rabies and Japanese encephalitis (JE) endemic countries, concomitant administration of travel vaccines within a short period is often required.
METHODS: The aim of this study was to determine whether an accelerated (one-week: Days 1-8) pre-exposure rabies (Rabipur(®), Novartis Vaccines) vaccination regimen administered concomitantly with a Japanese encephalitis (JE) vaccination (Ixiaro(®), Valneva) regimen, is non-inferior to the standard (four-week: Days 1, 8, 29) rabies regimen administered alone or concomitantly with the JE vaccine. Healthy adults (18 to ≤ 65 years) were randomized into Rabies + JE-Standard, Rabies + JE-Accelerated, Rabies-Standard and JE-Standard groups. Relative immunogenicity for rabies in each regimen was assessed using the rapid fluorescent focus inhibition test. Safety was evaluated up to and including Day 57.
RESULTS: Non-inferior immunogenicity for rabies was established between the Rabies + JE-Accelerated group compared to both the Rabies-Standard and Rabies + JE-Standard groups; as well as between the Rabies + JE-Standard regimen and the Rabies-Standard regimen. By Day 57, adequate neutralizing levels were achieved by 97-100% of subjects across all groups. Adverse events (AEs) were comparable for all groups.
CONCLUSIONS: An accelerated pre-exposure rabies and JE vaccination regimen is non-inferior to the standard four-week rabies regimen and may thus provide a more convenient regimen for individuals traveling to endemic countries at short notice. NCT01662440.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Japanese encephalitis; Rabies; Vaccination

Mesh:

Substances:

Year:  2015        PMID: 26005163     DOI: 10.1016/j.tmaid.2015.05.008

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  4 in total

Review 1.  [What is verified for travel vaccinations?]

Authors:  Tomas Jelinek
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 2.  Pre-exposure rabies prophylaxis: a systematic review.

Authors:  Jocelyn A Kessels; Sergio Recuenco; Ana Maria Navarro-Vela; Raffy Deray; Marco Vigilato; Hildegund Ertl; David Durrheim; Helen Rees; Louis H Nel; Bernadette Abela-Ridder; Deborah Briggs
Journal:  Bull World Health Organ       Date:  2016-11-25       Impact factor: 9.408

3.  Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Susan L Hills; Emmanuel B Walter; Robert L Atmar; Marc Fischer
Journal:  MMWR Recomm Rep       Date:  2019-07-19

4.  Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia.

Authors:  Nazmul Islam; Colleen Lau; Alan Leeb; Deborah Mills; Luis Furuya-Kanamori
Journal:  Hum Vaccin Immunother       Date:  2022-03-07       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.